帕米膦酸二钠同期放化疗治疗乳腺癌骨转移的疗效观察  

Clinical study of Bonin combined with concurrent chemoradiotherapy for breast cancer with bone metastasis

作　　者：冉体斌 陈绪元[2] 陈晓品[2] 

机构地区：[1]重庆市万州区人民医院肿瘤科,404000 [2]重庆医科大学附属第一医院肿瘤科,400016

出　　处：《重庆医学》2010年第21期2938-2939,2941,共3页Chongqing medicine

摘　　要：目的观察帕米膦酸二钠(博宁)加同期放化疗和同期放化疗治疗乳腺癌骨转移的疗效及安全性。方法将62例乳腺癌骨转移患者随机分为治疗组(31例)和对照组(31例)。治疗组静脉滴注博宁90 mg加同期放化疗,对照组单纯行同期放化疗。结果治疗组与对照组止痛有效率、活动能力改善率、生活质量提高率,骨质修复有效率分别为96.8%,93.5%,96.7%,71.0%和74.2%,71.0%,64.5%,38.7%,两组比较,差异具有统计学意义(P<0.05)。两组毒副反应较轻,差异无统计学意义(P>0.05)。结论博宁同期放化疗对乳腺癌骨转移患者,在止痛,活动能力,生活质量改善和骨质修复方面有明显疗效。Objctive To evaluate the effecacy and safety of Bonin combined with concurrent chemoradiotherapy for the treatment of breast cancer patients with bone metastases.Methods Six-two patients with metastatic tumor of bone were randomly divided in to Binin group（31cases） and control group（31cases）.The Bonin group received 90 mg pamidronate by intravenon infusion for 4 h and combined with concurrent chemordiotherapy;the control group was only treated with concurrent chemoradiotherapy.Results The overall response rates of the Bonin group and control group were 96.8% and 74.2%,respectively（P〈0.05）.The overall response rate of movement capacity improvement was 93.5% in the Binin group and 71.0% in the control group（P〈0.05）.The overall response rate of the life quality improvement was 96.7% in the Bonin group and 64.5%in the cotrol group（P〈0.01）.The overall response rate of bone mineral density recovery was 71.0% in the Bonin group and 38.7% in the control group（P〈0.05）The main side-effect in both group was bone merrow suppresion The incidence of leucopenia in the Bonin group was a little higher than that in the control group（P〈0.05）.Conclusion Bonin combined with concurrent chemoradiotherapy can remarkabily relieve bone pain,improve life quality,bone mineral density and movement ability in breast cancer patients with bone metastases.

关 键 词：骨转移癌 帕米膦酸二钠 放射治疗 化疗 

分 类 号：R737.9[医药卫生—肿瘤] R730.53[医药卫生—临床医学]